Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neural stem cell-derived exosomes are nano-sized extracellular vesicles (30–200 nm) secreted by neural stem cells (NSCs). These exosomes contain a variety of bioactive molecules including proteins, lipids, mRNAs, and microRNAs. They mediate intercellular communication and have demonstrated neuroprotective effects by promoting neurogenesis, angiogenesis, anti-apoptotic activity, anti-inflammatory responses, and repair of the blood-brain barrier. Mechanistically, they facilitate differentiation and maturation of neurons and glial cells—partly via delivery of specific miRNAs such as miR-9 or miR-124-3p—and can be engineered to deliver therapeutic agents like brain-derived neurotrophic factor (BDNF). Their ability to cross the blood-brain barrier makes them promising candidates for treating central nervous system diseases such as ischemic stroke and Alzheimer's disease[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neural stem cell-derived exosomes.